Cansino Biologics Inc.

Price Chart

Risk-Adjusted Performance

Also Listed On

Cansino Biologics Inc. (6185) Price Performance

Cansino Biologics Inc. (6185) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at HKD35.20.

Over the past year, 6185 has traded between a low of HKD30.40 and a high of HKD55.50. The stock has gained 14.7% over this period. It is currently 36.6% below its 52-week high.

Cansino Biologics Inc. has a market capitalization of $11.91B, with a price-to-earnings ratio of 438.65.

About Cansino Biologics Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Compare Cansino Biologics Inc.

Side-by-side comparison against top Healthcare peers.